4/A: Citius Oncology Director Awarded 300K Restricted Shares

Citius Oncology Director Eugene Myron received a grant of 300,000 restricted common stock shares, vesting in three years.

Summary

• Eugene Myron, a Director of Citius Oncology, Inc. (CTOR), was granted 300,000 shares of common stock.
• The transaction date for this acquisition was September 19, 2025.
• The shares were granted as restricted stock awards with a price of $0 per share.
• Following this transaction, Eugene Myron beneficially owns 300,000 shares of common stock.
• The shares will vest in full on the third anniversary of the grant date, subject to continuous service to Citius Oncology, Inc. or a Related Entity.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a director is a standard compensation practice that aligns management interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and long-term commitment.

Positives

• The grant of restricted stock aligns the director's long-term interests with those of the shareholders, incentivizing sustained performance.
• This type of compensation is a common practice to attract and retain experienced board members.

Negatives

• The future vesting of these shares could lead to potential dilution for existing shareholders if new shares are issued, or increased selling pressure if the shares are sourced from the open market upon vesting.

Risks

• The vesting of the 300,000 restricted stock awards is contingent upon the Reporting Person's Continuous Service to Citius Oncology, Inc. or a Related Entity as of the applicable vesting date.

Future Outlook

The 300,000 restricted stock awards granted to Director Eugene Myron are scheduled to vest in full on September 19, 2028, provided he maintains continuous service to Citius Oncology, Inc. or a related entity.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting of shares, but also benefit from aligned interests of a director with long-term company performance.

Next Steps

• The restricted stock awards will vest on the third anniversary of the grant date (September 19, 2028), subject to continuous service.

Key Dates

Keywords

Citius Oncology, CTOR, Restricted Stock Award, Insider Ownership, Form 4, Director Compensation, Equity Grant, Stock Vesting